168 related articles for article (PubMed ID: 21922392)
1. Update on adjuvant hormonal treatment of early breast cancer.
Lao Romera J; Puertolas Hernández TJ; Peláez Fernández I; Sampedro Gimeno T; Fernández Martínez R; Fernández Pérez I; Iranzo González Cruz V; Illarramendi Mañas JJ; Garcerá Juan S; Ciruelos Gil EM
Adv Ther; 2011 Sep; 28 Suppl 6():1-18. PubMed ID: 21922392
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant hormonal therapy in perimenopausal patients.
Pinto Marín A; Ballesteros García AI; Izarzugaza Perón Y; Mansó Sánchez L; López-Tarruella Cobo S; Zamora Auñón P
Adv Ther; 2011 Sep; 28 Suppl 6():39-49. PubMed ID: 21922394
[TBL] [Abstract][Full Text] [Related]
3. Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.
Strasser-Weippl K; Badovinac-Crnjevic T; Fan L; Goss PE
Breast; 2013 Aug; 22 Suppl 2():S171-5. PubMed ID: 24074782
[TBL] [Abstract][Full Text] [Related]
4. High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial.
Fontein DB; Nortier JW; Liefers GJ; Putter H; Meershoek-Klein Kranenbarg E; van den Bosch J; Maartense E; Rutgers EJ; van de Velde CJ
Eur J Surg Oncol; 2012 Feb; 38(2):110-7. PubMed ID: 22172646
[TBL] [Abstract][Full Text] [Related]
5. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
6. Aromatase inhibitors for the treatment and prevention of breast cancer.
Kalidas M; Brown P
Clin Breast Cancer; 2005 Apr; 6(1):27-37. PubMed ID: 15899070
[TBL] [Abstract][Full Text] [Related]
7. Initialization of adjuvant hormonal treatment for breast cancer.
Martínez Guisado A; Sánchez Muñoz A; de la Cabeza Lomas Garrido M; Ruíz Borrego M; Bayo Calero J; de Toro Salas R; González Mancha R; de la Haba Rodríguez J; Alba Conejo E
Adv Ther; 2011 Sep; 28 Suppl 6():66-84. PubMed ID: 21922396
[TBL] [Abstract][Full Text] [Related]
8. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
9. Individualization of treatment strategies.
Fernández Ortega A; Jolis López L; Viñas Villaró G; Villanueva Vázquez R; García Arias A; González Farré X; González Jiménez S; Saura Manich C; Cortés Castán J
Adv Ther; 2011 Sep; 28 Suppl 6():19-38. PubMed ID: 21922393
[TBL] [Abstract][Full Text] [Related]
10. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
13. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
[TBL] [Abstract][Full Text] [Related]
14. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
15. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
[TBL] [Abstract][Full Text] [Related]
16. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
17. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Monnier AM
Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
[TBL] [Abstract][Full Text] [Related]
18. The use of aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer.
Benson JR
J Clin Oncol; 2005 Sep; 23(27):6807-9. PubMed ID: 16170197
[No Abstract] [Full Text] [Related]
19. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.
Park IH; Ro J; Lee KS; Kim EA; Kwon Y; Nam BH; Jung SY; Lee S; Kim SW; Kang HS
J Clin Oncol; 2010 Jun; 28(16):2705-11. PubMed ID: 20421538
[TBL] [Abstract][Full Text] [Related]
20. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
Cataliotti L; Buzdar AU; Noguchi S; Bines J; Takatsuka Y; Petrakova K; Dube P; de Oliveira CT
Cancer; 2006 May; 106(10):2095-103. PubMed ID: 16598749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
